8-KItem 8.01 · Other EventsItem 9.01 · Financial Statements

AbbVie 8-K (Item 9.01) — Supplemental Indenture No.

Filed with the SEC on March 4, 2026 · Summarized by InvestorsBot

AbbVie 8-K (Item 9.01) — Supplemental Indenture No. 12 executed Mar 4, 2026 between AbbVie Inc. and U.S. Bank Trust Co., N.A. (trustee); related exhibits filed with the report. $ABBV 📄 #Debt #SECfilings

Exhibits include forms of notes: Floating‑rate due 2028; 3.775% due 2028; 4.125% due 2031; 4.400% due 2033; 4.750% due 2036; 5.550% due 2056; 5.650% due 2066 (in Exhibit 4.2). $ABBV 💵 #Bonds #FixedIncome

Wachtell, Lipton, Rosen & Katz provided legal opinion and consent dated Mar 4, 2026 re: the Notes (Exhibit 5.1 & 23.1). 8‑K signed by CFO Scott T. Reents on Mar 4, 2026. $ABBV ⚖️ #CorporateFinance #SECfilings

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from AbbVie Inc.

On Mar 4, 2026 AbbVie completed an $8.0B notes offering: $750M floating-rate due 2028; $1.5B 3.775% due…

8-K · March 4, 2026

AbbVie ($ABBV) filed Form 8‑K (Item 9.01) attaching an Underwriting Agreement dated Feb 24, 2026 among…

8-K · February 26, 2026

AbbVie ($ABBV) 2/24/26 agreed to sell $8.0B of senior notes across seven tranches (2028–2066); pricing…

8-K · February 26, 2026

AbbVie files Form 8‑K dated Feb 4, 2026: furnishes press release (Exhibit 99.1) pursuant to Item 2.02;…

8-K · February 4, 2026

AbbVie ($ABBV) issued a press release on Feb 4, 2026 announcing Q4 & FY 2025 financial results.

8-K · February 4, 2026

AbbVie filed an 8‑K on Jan 7, 2026.

8-K · January 7, 2026